Skip to main content
  1. Tumor Microenvironment (TME)
    • Tumor Microenvironment (TME)
    Sonoma
    Sponsor Led Poster Session: Preclinical models of the tumor microenvironment: translational value and derisking clinical trials
    Cytotoxic T-cells (CTLs) in the tumor microenvironment (TME) orchestrate anti-tumor immunity. Immuno ...
  2. Tumor Microenvironment (TME)
    • Tumor Microenvironment (TME)
    Sonoma
    Preclinical models of the tumor microenvironment: translational value and derisking clinical trials
  3. Clinical Development
    • Clinical Development
    Mendocino
    Project Optimus – The impact on protocol design and requirements
    FDA on going design requirements Applications to C> Global impact Cohort management
  4. Translational Research
    • Translational Research
    Muir Woods
    Early-stage characterization and selection of immuno-oncology leads through in-vitro cell-based assays and beyond
    From checkpoint inhibitors towards neoepitope vaccines, does one size fits it all? Fit for purpose i ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Afternoon Refreshments
    37 North Fireplace Side
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Evening Drinks Reception
    Courtyard
  5. Tumor Microenvironment (TME)
    • Tumor Microenvironment (TME)
    Sonoma
    Induction of checkpoints and other components of tumor immunity Breaching the TME Tumor cell killing ...
  6. Clinical Development
    • Clinical Development
    Mendocino
    How to accelerate the determination of safety and clinical benefit Can the assessment of immune chan ...
  7. Immune Biomarkers
    • Immune Biomarkers
    Monterey
    Complex immune system Identifying biomarkers predictive of response to immunotherapy Technical chall ...
  8. Translational Research
    • Translational Research
    Sierra B
    Sponsor Led Poster Session: Single-cell multiomic clonal tracking in myeloma identifies SMM clones that progress to MM and low frequency MM clones with resistance features enabling more precise application of targeted therapies
    Multiple myeloma (MM) is a cancer of plasma cells with approximately 200,000 new cases/year and a 54 ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Sierra B
    Spotlight Presentation: Deciphering the Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes
    The Tumor Immune Microenvironment (TIME) plays a crucial role in response to immunotherapies, the en ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    1-2-1 Meetings / Networking Break
    1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    1-2-1 Meetings / Networking Break
    1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Sierra B
    Spotlight Presentation: NGS in Immuno-oncology: Current Advancements and Ongoing Challenges
    The applications of next-generation sequencing (NGS) are playing an emerging role in immune-oncology ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Networking Lunch
    Courtyard
  9. Immune Biomarkers
    • Immune Biomarkers
    Monterey
    Translational Research topic: The value of multiomics on tissue: Emerging trends and insights in immuno-oncology
    How can multiomics approaches on tissue samples drive deeper insights into immune system interaction ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Morning Refreshments
    37 North Fireplace Side
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    1-2-1 Meetings / Networking Break
    1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    1-2-1 Meetings / Networking Break
    1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)
  10. Tumor Microenvironment (TME)
    • Tumor Microenvironment (TME)
    Sonoma
  11. Clinical Development
    • Clinical Development
    Mendocino
    Why is resistance (e.g., primary and secondary) to PD(L1)-1 inhibitors a significant clinical proble ...
  12. Translational Research
    • Translational Research
    Muir Woods
    Ways to determine FiH dose for oncology trials with immune cell engaging multi-specific antibodies A ...
  13. Immune Biomarkers
    • Immune Biomarkers
    Monterey
    Is it ready for prime time?  Do we have sufficient data? Is there consensus around a standardized as ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Sierra B
    Opening Address & Keynote Presentation: Unlocking Tumor-Immune Dynamics: How TruTumor Histoculture Reveals Insights into Head and Neck Cancer Responses to Checkpoint Therapy
    Dynamic interactions within the tumor microenvironment influence patient responses to immune-modulat ...
    • Immune Biomarkers
    • Translational Research
    • Clinical Development
    • Tumor Microenvironment (TME)
    Registration
    37 North Fireplace Side